Albireo Pharma Inc Capitalisation boursière
Quel est le Capitalisation boursière de Albireo Pharma Inc?
Le Capitalisation boursière de Albireo Pharma Inc est $492.28M
Quelle est la définition de Capitalisation boursière?
La capitalisation boursière est la valeur marchande à un moment donné des actions en circulation d'une société cotée en bourse, étant égale au cours de l' action à ce moment-là, multiplié par le nombre d'actions en circulation .
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Capitalisation boursière des entreprises dans Health Care secteur sur NASDAQ par rapport à Albireo Pharma Inc
Que fait Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Entreprises avec capitalisation boursière similaire à Albireo Pharma Inc
- NOCIL a Capitalisation boursière de $491.44M
- Nektar Therapeutics a Capitalisation boursière de $491.50M
- Tejon Ranch Co a Capitalisation boursière de $491.61M
- Sisram Medical Ltd a Capitalisation boursière de $491.70M
- enCore a Capitalisation boursière de $491.81M
- Garrett Motion Inc a Capitalisation boursière de $491.97M
- Albireo Pharma Inc a Capitalisation boursière de $492.28M
- Brasilagro Companhia Brasileira De Propriedade Agricola a Capitalisation boursière de $492.33M
- Premier Gold Mines a Capitalisation boursière de $493.21M
- Beijing Enterprises Clean a Capitalisation boursière de $493.64M
- Xinyuan Ppty Mgmt Svc a Capitalisation boursière de $493.73M
- IQE Plc a Capitalisation boursière de $494.04M
- South Plains Inc a Capitalisation boursière de $494.72M